Evaluating the clinical efficacy of combinatorial pharmacogenomic‐guided treatment in schizophrenia patients
British Journal of Clinical Pharmacology · 2026-08 · 92 (8) · 2809-2818
DOI: 10.1002/bcp.70568 ↗At a glance
Journal article in British Journal of Clinical Pharmacology, published online on 2026-04-22. Written by Jiqing Li and 4 co-authors. Institution: Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China. Major MEDLINE topics: Schizophrenia, Antipsychotic Agents. 26 references. The full text is freely available in PubMed Central. Funded by: Shandong Province Natural Science Foundation, Youth Branch, General Fund of China Postdoctoral Science Foundation.
Abstract (original language)
Aims
This study aims to evaluate the impact of combinatorial pharmacogenomic (CPGx)‐guided treatment (CPGT) on medication patterns, symptom remission and hospital stay in patients with schizophrenia.
Methods
This retrospective study included schizophrenia patients hospitalized at Shandong Mental Health Center from 2019 to 2022 who underwent self‐paid CPGx testing. Based on the temporal sequence of CPGx testing relative to hospitalization, their hospitalizations were classified into the CPGT and the treatment‐as‐usual (TAU) group. The χ 2 and Kruskal–Wallis tests were used to compare the antipsychotics use rate and dosage between the two groups, respectively, and the generalized estimating equation was used to evaluate the effect of CPGx on the percentage change in the Positive and Negative Syndrome Scale (PANSS) score, response and hospital stay.
Results
This study included 895 hospitalization records from 494 patients with schizophrenia, with 331 in the CPGT and 564 in the TAU. CPGT added genotype‐related prescriptions such as amisulpride, aripiprazole, risperidone and clozapine in the superior genotype subgroup ( P < 0.05), reduced the dosage of risperidone in the slow metabolism subgroup, and increased the doses of clozapine, risperidone, quetiapine and olanzapine in the fast metabolism subgroup ( P < 0.05). Compared with TAU, CPGT was associated with a higher percentage change in PANSS score during hospitalization ( β = 6.79, 95% CI: 3.26–10.33) and a higher response rate (OR = 1.62; 95% CI, 1.21–2.16). Additionally, the hospital stay in the CPGT group was reduced by 4.80 (95% CI, 1.92–7.68) days.
Conclusions
Our findings demonstrate that CPGx significantly improves treatment outcomes in hospitalized patients with schizophrenia, supporting that CPGx can guide treatment.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, China.
- Department of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China.
- Healthcare Big Data Research Institute, Cheeloo College of Medicine, Shandong University, Jinan, China.
- Science and Education Section, Shandong Mental Health Center, Shandong University, Jinan, China.
- Jinan Center for Disease Control and Prevention, Jinan, China.
ORCID profiles: Jiqing Li
Funding
- Shandong Province Natural Science Foundation, Youth Branch
- General Fund of China Postdoctoral Science Foundation
Cite
APA
Li, J., Xia, W., Fu, P., Yu, T., & Xue, F. (2026). Evaluating the clinical efficacy of combinatorial pharmacogenomic‐guided treatment in schizophrenia patients. British Journal of Clinical Pharmacology, 92(8), 2809-2818. https://doi.org/10.1002/bcp.70568
Vancouver
Li J, Xia W, Fu P, Yu T, Xue F. Evaluating the clinical efficacy of combinatorial pharmacogenomic‐guided treatment in schizophrenia patients. British Journal of Clinical Pharmacology. 2026;92(8):2809-2818. doi:10.1002/bcp.70568
BibTeX
@article{Li2026,
author = {Li, Jiqing and Xia, Weili and Fu, Ping and Yu, Tiangui and Xue, Fuzhong},
title = {Evaluating the clinical efficacy of combinatorial pharmacogenomic‐guided treatment in schizophrenia patients},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
volume = {92},
number = {8},
pages = {2809--2818},
doi = {10.1002/bcp.70568}
}
EUVIMED